
Sign up to save your podcasts
Or


Send us a text
In this episode of Small Cap Spotlight x WTR Healthcare Happenings podcast, WTR's Tim Gerdeman, and Robert Sassoon welcomes back Nick Kadysh, Founding CEO and President of PharmAla Biotech (OTCQB: MDXXF). The discussion explores the evolving global regulatory environment for psychedelics—particularly MDMA—the ripple effects of the Lykos Therapeutics FDA Complete Response Letter (CRL) disclosures, and PharmAla’s strategic approach to research, manufacturing, and commercialization of clinical-grade MDMA and next-generation analogues.
By Water Tower Research5
88 ratings
Send us a text
In this episode of Small Cap Spotlight x WTR Healthcare Happenings podcast, WTR's Tim Gerdeman, and Robert Sassoon welcomes back Nick Kadysh, Founding CEO and President of PharmAla Biotech (OTCQB: MDXXF). The discussion explores the evolving global regulatory environment for psychedelics—particularly MDMA—the ripple effects of the Lykos Therapeutics FDA Complete Response Letter (CRL) disclosures, and PharmAla’s strategic approach to research, manufacturing, and commercialization of clinical-grade MDMA and next-generation analogues.

228,886 Listeners

3,213 Listeners

3,376 Listeners

1,283 Listeners

9,545 Listeners

1,202 Listeners

9,438 Listeners

112,401 Listeners

2,027 Listeners

1,043 Listeners

196 Listeners

10,015 Listeners

248 Listeners

1,429 Listeners

20 Listeners